Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.37 |
| ▸ | SELE | P16581 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8762373 | 0.90 | MAPT (0.47) | RAB9AALDH1A1MAPTNPC1HPGD | |
| SCHEMBL8490127 | 0.90 | MAPT (0.47) | RAB9AALDH1A1MAPTNPC1HPGD | |
| SCHEMBL16492373 | 0.90 | MAPT (0.47) | RAB9AALDH1A1MAPTNPC1HPGD | |
| SCHEMBL8762102 | 0.88 | MAPT (0.53) | RAB9AALDH1A1MAPTNPC1HPGD | |
| SCHEMBL8543828 | 0.85 | SMN1; SMN2 (0.46) | RAB9AALDH1A1MAPTNPC1HPGD | |
| SCHEMBL15054858 | 0.85 | RAB9A (0.65) | RAB9AALDH1A1MAPTNPC1HPGD | |
| SCHEMBL31225194 | 0.85 | RAB9A (0.65) | RAB9AALDH1A1MAPTNPC1HPGD | |
| SCHEMBL21104547 | 0.84 | ALDH1A1 (0.52) | RAB9AALDH1A1MAPTNPC1HPGD | |
| SCHEMBL1855537 | 0.84 | MAPT (0.41) | RAB9AALDH1A1MAPTNPC1HPGD | |
| SCHEMBL12937226 | 0.83 | HSPB1 (0.54) | RAB9AALDH1A1MAPTNPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113616648-A | Notch signaling pathway inhibitors and their use in cancer treatment | 洛桑联邦理工学院(EPFL) | 2021-11-09 | — | — | CN | claimed |
| US-20190219566-A1 | METHOD FOR IDENTIFYING MODULATORS OF NOTCH SIGNALING | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2019-07-18 | — | — | US | claimed |
| EP-3332783-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | Ecole Polytechnique Fédérale de Lausanne (EPFL) (CH) | 2018-06-13 | — | — | EP | claimed |
| EP-2793884-B1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) | 2017-11-29 | — | — | EP | claimed |
| US-9296682-B2 | Inhibitors of notch signalling pathway and use thereof in treatment of cancers | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2016-03-29 | — | — | US | claimed |
| EP-3332783-B1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) | 2024-12-04 | — | — | EP | disclosed |
| CN-119019324-A | Process for preparing aminodiaryl ethers and aminodiaryl ether hydrochlorides | 塞莱斯蒂亚生物技术股份公司 | 2024-11-26 | — | — | CN | disclosed |
| US-20220185793-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | CELLESTIA BIOTECH AG (CH) | 2022-06-16 | — | — | US | disclosed |
| EP-3952997-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | Cellestia Biotech AG (CH) | 2022-02-16 | — | — | EP | disclosed |
| CN-114007696-A | Compounds for treating oncovirus-induced cancer and methods of use thereof | 塞莱斯蒂亚生物技术股份公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20210382038-A1 | METHOD FOR IDENTIFYING MODULATORS OF NOTCH SIGNALING | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2021-12-09 | — | — | US | disclosed |
| US-20210382038-A1 | METHOD FOR IDENTIFYING MODULATORS OF NOTCH SIGNALING | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2021-12-09 | — | — | US | disclosed |
| US-9296682-B2 | Inhibitors of notch signalling pathway and use thereof in treatment of cancers | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2016-03-29 | — | — | US | disclosed |
| US-9296682-B2 | Inhibitors of notch signalling pathway and use thereof in treatment of cancers | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2016-03-29 | — | — | US | disclosed |
| US-20140329867-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20140329867-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20140329867-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) | 2014-11-06 | — | — | US | disclosed |
| EP-2793884-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | Ecole Polytechnique Federale de Lausanne (EPFL) (CH) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013093885-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | Ecole polytechnique fédérale de Lausanne (EPFL) (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013093885-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | Ecole polytechnique fédérale de Lausanne (EPFL) (CH) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210382038-A1 | METHOD FOR IDENTIFYING MODULATORS OF NOTCH SIGNALING | NOTCH3, NOTCH1, NOTCH4 | RAB9A 3388/4885ALDH1A1 3224/4885MAPT 3343/4885 |
| US-20190219566-A1 | METHOD FOR IDENTIFYING MODULATORS OF NOTCH SIGNALING | NOTCH3, NOTCH1, NOTCH4 | RAB9A 3388/4885ALDH1A1 3224/4885MAPT 3343/4885 |
| US-20220185793-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | TP53, HAVCR2, AQP1 | RAB9A 398/4885ALDH1A1 819/4885MAPT 2780/4885 |
| US-20140329867-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | NOTCH3, NOTCH1, NOTCH4 | RAB9A 3103/4885ALDH1A1 2582/4885MAPT 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.